POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: blondbeauty on June 11, 2006, 08:29:33 pm
-
That is what I have just read in a spanish website. The original article is mexican:
http://www.vihpositivo.com/nuevamedicina100606.htm
Ilustration:
http://www.milenio.com/MediaCenter/Fotos/2006/Junio/10/ten-32-1pfg.jpg
-
shame i cant read spanish.... :(
-
can anyone translay this info on p457
-
I prefer not to use one of those horrible automatic translations. So here goes a summary:
PA-457 from panacos is the first of a new family of tools against HIV infection. Reduces viral load in a 90% used as monotherapy. This same month trials will comence in combination with current antirretrovirals. If succesfull it will be in the market by 2009...
...PA-457 works in a completely different way: inactivating the formation of the caspid or the cone in the interior of the virus. A shell that protects the viral ARN from any external attack...looking through the microscope scientists could see how this works: HIv has a protein called Gag wich is cut into small pieces that form the caspid. PA-457 adheres to it preventing the protein gag from being cut properly and, instead of forming a protective cone, the caspid ends up being like a ball full of holes leaving the viral ARN unprotected. The virus is released from the host cell but its unable to infect other cells. Its a "dead" virus.
Another important fact is that PA-457 molecule only adheres to the gag protein after it has been formed preventing the formation of the caspid.
The trial will start with 48 patients with resistance issues combining their failing therapies with PA-457 or a placebo.
Panacos scientists are very excited but Allaway, reminds us there are still many steps to follow before it reaches the market and not before 2009.
This medication showed a 10% decrease in Viral load after a few hours of the first dose in humans.
It also showed a great antiviral activity in the animal model SCDI. It reduced viral load in mouses up to a 90%.
Pharmacinegetic tests in people were positive. Oral doses above 250 mg were well tolerated. In doses above 50 mg it mantained efective levels even after 24, which is something very desirable in these type of meds.
My transalation is not very good but the original is poorly writen and contents a bit untidy and messed up.
The study has been published in june´s Journal of Virology. A less tecnical version is available in "New Scientist"
-
Thanks heaps for the heads up and the translation Juan.
Cheers
Matt
-
In English! ;D
http://www.newscientist.com/article/mg19025554.400-trials-for-drug-that-leaves-hiv-defenceless.html
-
PA-457 will be named Bevirimat.
First hand information from Panacos. Phase 2b: http://phx.corporate-ir.net/phoenix.zhtml?c=75423&p=irol-newsArticle&ID=871292&highlight
-
Tenfold reduction in a matter of hours...now that is what I called efficacy.
-
Maybe these type of drugs (maturation inhibitors, integrase inhibitors...) are the piece of the puzzle we are missing in current HAART to clear the infection.
Remember this paragraf from a link I posted months ago?
"But Hamer also retains a guarded optimism shared by many reservoir researchers. "There's no evidence that HIV is genetically programmed to persist in the body," he says. Instead, he argues, the virus simply benefits from the limits of current therapy. "So eradication might actually turn out to be quite simple. Nobody knows. Adding one right drug to HAART may push the virus down to a level where it doesn't rebound. There's no evidence that's not the case."
http://www.iavireport.org/Issues/Issue9-5/reservoir.asp
-
I was thinking about that statement precisely when I read the news about Bevirimat (might as well use their name now!). I think it's entirely possible that one day we'll hear that a volunteer (s) has been totally cleared as a result of participating in one of these trials that use new, effective therapies that block 100% of replication. Anti-tat for example (here I go again, talking about tat!), holds a lot of potential because it seems to totally block active replication. In any case, Bevirimat, whether it does clear infection or not, will be a fantastic thing because it seems to overcome resistance issues. J.